Insider Buying: Kailera Therapeutics (NASDAQ:KLRA) Director Buys $134,375,008.00 in Stock

Kailera Therapeutics, Inc. (NASDAQ:KLRA) Director Andrew Kaplan purchased 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the acquisition, the director owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. This represents a 47.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Kailera Therapeutics Price Performance

Shares of NASDAQ:KLRA opened at $24.30 on Thursday. Kailera Therapeutics, Inc. has a 1 year low of $23.65 and a 1 year high of $28.23.